These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 26888854

  • 1. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
    Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, Ascherman DP, Levesque MC.
    Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
    [Abstract] [Full Text] [Related]

  • 2. Anti-signal recognition particle autoantibody ELISA validation and clinical associations.
    Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, Qi Z, Koontz D, Levesque MC.
    Rheumatology (Oxford); 2015 Jul; 54(7):1194-9. PubMed ID: 25524922
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
    Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L.
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
    [Abstract] [Full Text] [Related]

  • 5. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.
    Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP.
    Arthritis Rheum; 2007 Sep; 56(9):3125-31. PubMed ID: 17763431
    [Abstract] [Full Text] [Related]

  • 6. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
    Li S, Ge Y, Yang H, Wang T, Zheng X, Peng Q, Lu X, Wang G.
    Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
    Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, Qi Z, Koontz D, Levesque MC.
    Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA.
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.
    Kryštůfková O, Barbasso Helmers S, Venalis P, Malmström V, Lindroos E, Vencovský J, Lundberg IE.
    Arthritis Res Ther; 2014 Oct 10; 16(5):454. PubMed ID: 25301447
    [Abstract] [Full Text] [Related]

  • 14. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis.
    Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK.
    Clinics (Sao Paulo); 2013 Jul 10; 68(7):909-14. PubMed ID: 23917652
    [Abstract] [Full Text] [Related]

  • 15. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y, Ishikawa A, Sugiura K, Akiyama M.
    Rheumatology (Oxford); 2012 Aug 10; 51(8):1508-13. PubMed ID: 22539482
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies.
    Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN.
    J Autoimmun; 1999 Mar 10; 12(2):137-42. PubMed ID: 10047434
    [Abstract] [Full Text] [Related]

  • 18. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
    Zhang L, Yang H, Yang H, Liu H, Tian X, Jiang W, Peng Q, Wang G, Lu X.
    Semin Arthritis Rheum; 2022 Aug 10; 55():152011. PubMed ID: 35489170
    [Abstract] [Full Text] [Related]

  • 19. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.
    López De Padilla CM, Crowson CS, Hein MS, Strausbauch MA, Aggarwal R, Levesque MC, Ascherman DP, Oddis CV, Reed AM.
    Clin Exp Rheumatol; 2015 Aug 10; 33(5):655-63. PubMed ID: 26446265
    [Abstract] [Full Text] [Related]

  • 20. Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients.
    Hulejová H, Kryštůfková O, Mann H, Klein M, Pavlíčková K, Zámečník J, Vencovský J, Šenolt L.
    Clin Exp Rheumatol; 2016 Aug 10; 34(2):222-9. PubMed ID: 26886056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.